The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy
The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
AT‐IAP (1‐{6‐[(4‐fluorophenyl)methyl]‐3,3‐dimethyl‐1H,2H,3H‐pyrrolo[3,2‐b]pyridin‐1‐yl}‐2‐[(2R,5R)‐5‐methyl‐2‐{[(3R)‐3‐methylmorpholin‐4‐yl]methyl}piperazin‐1‐yl]ethan‐1‐one) was identified as a novel potent non‐alanine small molecule dual inhibitor of cIAP1/XIAP protein. AT‐IAP was assessed in preclinical species, demonstrating favorable bioavaila...
Alternative Titles
Full title
The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e8c8c3ab0275432482ed48a188db291c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e8c8c3ab0275432482ed48a188db291c
Other Identifiers
ISSN
2052-1707
E-ISSN
2052-1707
DOI
10.1002/prp2.70030
